Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Rein Therapeutics, Inc. (RNTX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2017
2018
2019
2020
2021
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $11.0M | $14.2M | $4.0M | $18.0M | $17.0M | $11.2M | $17.7M | $18.4M | $14.2M | $10.3M | $7.8M |
| Operating expenses | $50.6M | $65.1M | $16.3M | $27.6M | $26.6M | $20.5M | $30.0M | $31.9M | $23.0M | $18.2M | $12.9M |
| Operating income | −$50.6M | −$65.1M | −$16.3M | −$27.6M | −$26.6M | −$20.5M | −$30.0M | −$31.9M | −$23.0M | −$18.2M | −$12.9M |
| EBITDAderived | −$50.6M | −$65.0M | −$16.2M | −$27.5M | −$26.5M | −$20.3M | −$29.8M | −$31.7M | −$22.9M | −$17.9M | −$12.6M |
| Net income | −$49.9M | −$62.9M | −$15.7M | −$27.3M | −$26.2M | −$27.3M | −$29.4M | −$31.5M | −$22.6M | −$18.1M | −$12.9M |
| Basic EPSper diluted share | -$1.96 | -$3.51 | -$3.42 | -$6.02 | -$5.89 | -$0.61 | -$1.20 | -$2.14 | -$3.04 | -$42.35 | -$32.31 |
| Diluted EPSper diluted share | -$1.96 | -$3.51 | -$3.42 | -$6.02 | -$5.89 | -$0.61 | -$1.20 | -$2.14 | -$3.04 | -$42.35 | -$32.31 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 27, 2026Form 4 | VON RICKENBACH JOSEF HDirector | BuyCommon stock , $0.001 par value | 4.5K | $1.07 | $4.8K | 62.5K |
| May 26, 2026Form 4 | VON RICKENBACH JOSEF HDirector | BuyCommon stock , $0.001 par value | 23.2K | $1.06 | $24.6K | 58.0K |
| May 22, 2026Form 4 | VON RICKENBACH JOSEF HDirector | BuyCommon stock , $0.001 par value | 15.9K | $1.05 | $16.7K | 34.8K |
| May 21, 2026Form 4 | VON RICKENBACH JOSEF HDirector | BuyCommon stock , $0.001 par value | 3.4K | $1.04 | $3.6K | 18.9K |
| Apr 30, 2026Form 4 | WINDSOR JAMES BRIANSee Remarks | BuyCommon stock , $0.001 par value | 25.0K | $1.00 | $25.0K | 27.0K |